S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Competitors

$3.31
0.00 (0.00%)
(As of 09:30 AM ET)
Compare
Today's Range
$3.31
$3.31
50-Day Range
$2.72
$3.39
52-Week Range
$2.19
$6.13
Volume
3,216 shs
Average Volume
159,069 shs
Market Capitalization
$62.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

ABEO vs. ADAG, LFVN, GLTO, GANX, LTRN, FIXX, IOBT, ENOB, CNTB, and ANEB

Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Adagene (ADAG), LifeVantage (LFVN), Galecto (GLTO), Gain Therapeutics (GANX), Lantern Pharma (LTRN), Homology Medicines (FIXX), IO Biotech (IOBT), Enochian Biosciences (ENOB), Connect Biopharma (CNTB), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.

Abeona Therapeutics vs.

Adagene (NASDAQ:ADAG) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.

Adagene currently has a consensus price target of $5.00, indicating a potential upside of 275.94%. Abeona Therapeutics has a consensus price target of $40.00, indicating a potential upside of 995.89%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Abeona Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Abeona Therapeutics received 495 more outperform votes than Adagene when rated by MarketBeat users. However, 76.19% of users gave Adagene an outperform vote while only 71.17% of users gave Abeona Therapeutics an outperform vote.

CompanyUnderperformOutperform
AdageneOutperform Votes
16
76.19%
Underperform Votes
5
23.81%
Abeona TherapeuticsOutperform Votes
511
71.17%
Underperform Votes
207
28.83%

In the previous week, Abeona Therapeutics had 6 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Abeona Therapeutics and 0 mentions for Adagene. Abeona Therapeutics' average media sentiment score of 0.57 beat Adagene's score of 0.49 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Adagene Neutral
Abeona Therapeutics Positive

Adagene has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Abeona Therapeutics has lower revenue, but higher earnings than Adagene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$9.29 million6.19-$79.97 millionN/AN/A
Abeona Therapeutics$1.41 million44.09-$39.70 millionN/AN/A

Adagene's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Adagene N/A N/A N/A
Abeona Therapeutics N/A -132.14% -53.24%

13.7% of Adagene shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abeona Therapeutics beats Adagene on 8 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABEO vs. The Competition

MetricAbeona TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$62.16M$5.71B$4.45B$6.26B
Dividend YieldN/A2.61%5.95%6.50%
P/E RatioN/A4.0182.7311.17
Price / Sales44.09325.943,368.0487.37
Price / CashN/A20.1522.0023.57
Price / Book2.124.974.735.53
Net Income-$39.70M$186.08M$115.49M$192.15M
7 Day Performance5.41%8.02%121.56%9.32%
1 Month Performance0.91%5.63%123.55%11.03%
1 Year Performance-16.94%18.94%135.83%1.57%

Abeona Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
2.0395 of 5 stars
$1.32
-6.4%
$5.00
+278.8%
-52.5%$57.09M$9.29M0.00198High Trading Volume
LFVN
LifeVantage
1.2577 of 5 stars
$4.60
+0.9%
N/A+8.5%$58.88M$206.36M-76.67263Analyst Report
High Trading Volume
GLTO
Galecto
1.8676 of 5 stars
$2.30
+2.7%
$11.67
+407.2%
+11.7%$59.04MN/A-1.0128
GANX
Gain Therapeutics
2.2357 of 5 stars
$4.59
flat
$8.15
+77.6%
+40.9%$56.60M$140,000.00-2.8225Positive News
LTRN
Lantern Pharma
1.5062 of 5 stars
$5.47
+13.0%
$11.00
+101.1%
-12.0%$59.40MN/A-4.2414Positive News
FIXX
Homology Medicines
2.4835 of 5 stars
$0.97
-4.9%
$6.85
+606.1%
-44.0%$56.06M$3.21M-0.44224
IOBT
IO Biotech
1.8548 of 5 stars
$2.07
+2.0%
$11.00
+431.4%
-60.4%$59.66MN/A-0.8319Negative News
Gap Up
ENOB
Enochian Biosciences
0 of 5 stars
$0.94
flat
N/A-77.1%$55.02MN/A-1.1511Upcoming Earnings
Gap Up
High Trading Volume
CNTB
Connect Biopharma
2.5789 of 5 stars
$1.11
-4.3%
$7.00
+530.7%
+53.9%$61.09MN/A0.0062Positive News
Gap Down
ANEB
Anebulo Pharmaceuticals
2.1442 of 5 stars
$2.13
-10.5%
$7.00
+228.6%
-16.1%$54.59MN/A-4.532

Related Companies and Tools

This page (NASDAQ:ABEO) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -